PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells

BACKGROUND: Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-based therapies have transformed cancer treatment. Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1(high) tumors. Our study provides new information on the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajor, Malgorzata, Graczyk-Jarzynka, Agnieszka, Marhelava, Katsiaryna, Burdzinska, Anna, Muchowicz, Angelika, Goral, Agnieszka, Zhylko, Andriy, Soroczynska, Karolina, Retecki, Kuba, Krawczyk, Marta, Klopotowska, Marta, Pilch, Zofia, Paczek, Leszek, Malmberg, Karl-Johan, Wälchli, Sébastien, Winiarska, Magdalena, Zagozdzon, Radoslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796262/
https://www.ncbi.nlm.nih.gov/pubmed/35078921
http://dx.doi.org/10.1136/jitc-2021-002500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796262/
https://www.ncbi.nlm.nih.gov/pubmed/35078921
http://dx.doi.org/10.1136/jitc-2021-002500

Ejemplares similares